Plasma NT-proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease

Blood Pressure

Volumn 14, Issue 2, 2005, Pages 99-106

  Svensson, Per ^a   de Faire, Ulf ^a,b   Niklasson, Urban ^a   Hansson, Lars Olof ^a   Östergren, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Blood pressure; Hypertrophy; Natriuretic peptides; Peripheral vascular disease; Scintigraphy

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; N TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AMBULATORY MONITORING; ARTERY DISEASE; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION FUNCTION; ELECTROCARDIOGRAPHY; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HORMONE BLOOD LEVEL; HUMAN; HYPOTHESIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PULSE PRESSURE; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

AGED; ARTERIES; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; VASCULAR DISEASES;

EID: 18444405859     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050510008931     Document Type: Article

References (30)

1. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000;18:1121-1128.
2. Arnlov J, Lind L, Stridsberg M, Andren B, Lithell H. N-terminal atrial natriuretic peptide and left ventricular geometry and function in a population sample of elderly males. J Intern Med. 2000;247:699-708.
3. Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann M, Riegger GA, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension. 2002;39:99-104.
4. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003;24:1710-1718.
5. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart. 1997;77:264-267.
6. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med. 1972;287:781-787.
7. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med. 1988;108:7-13.
8. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. JAMA. 2002;288: 1252-1259.
9. Svensson P, de Faire U, Niklasson U, Ostergren J. Office blood pressure underestimates ambulatory blood pressure in peripheral arterial disease in comparison to healthy controls. J Hum Hypertens. 2004;18:193-200.
10. Rose G. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27:645-658.
11. O'Shea JC, Murphy MB. Ambulatory blood pressure monitoring: which arm? J Hum Hypertens. 2000;14:227-230.
12. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I, et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994;74:714-719.
13. Bone D, Holmgren A, Svane B. Thallium tomography in the detection of myocardial perfusion defects. Acta Med Scand Suppl. 1985;694:109-119.
14. Theodorsen L. Dry reagent technology. Kodak Ektachem 700 XR in clinical enzymology. Scand J Clin Lab Invest. 1993;215 Suppl:101-111.
15. Weets I, Gorus FK, Gerlo E. Evaluation of an immunoturbidimetric assay for haemoglobin A1c on a Cobas Mira S analyser. Eur J Clin Chem Clin Biochem. 1996;34:449-453.
16. Nauck M, Marz W, Jarausch J, Cobbaert C, Sagers A, Bernard D, et al. Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment. Clin Chem. 1997;43:1622-1629.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
18. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40:437-445.
19. Kato J, Kitamura K, Uemura T, Kuwasako K, Kita T, Kangawa K, et al. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: Their relations to age and pulse pressure. Hypertens Res. 2002;25:887-892.
20. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail. 2003;5:599-606.
21. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure: A potent predictor of total cardiovascular risk in hypertension. Hypertension. 1998;32:983-988.
22. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart. 2002;87:97-98.
23. Nichols WW, Edwards DG. Arterial elastance and wave reflection augmentation of systolic blood pressure: deleterious effects and implications for therapy. J Cardiovasc Pharmacol Ther. 2001;6:5-21.
24. Nichols WW, O'Rourke MF. McDonalds's blood flow in arteries, 4th edition. London: Arnold, 1998.
25. Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond). 2002;103: 493-499.
26. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med. 2002;40:371-377.
27. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol. 2002;40:976-982.
28. Kario K, Nishikimi T, Yoshihara F, Takishita S, Yamaoka R, Matsuo T, et al. Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: Relationships to 24 h blood pressure. J Hypertens. 1998;16: 1253-1259.
29. Geshi E, Koba S, Suzuki H, et al. The role of autonomic nervous system activity in the target organ damages of hypertensive patients. In: 26th International Congress of Internal Medicine; 2002. 2-PO-166.
30. Luchner A, Brockel U, Muscholl M, Hense HW, Doring A, Riegger GA, et al. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: A population-based study. Cardiovascular Res. 2002;53: 720-727.